ACADIA Pharmaceuticals, Inc. (ACAD) Advances AM-831 to Phase 1 Stage
ACADIA Pharmaceuticals is a biopharmaceutical company that uses innovative technology to fuel drug discovery and development of novel treatments for central nervous system disorders. The company currently has four product candidates in various stages of development. The company today announced that the U.S. Food and Drug Administration has completed its review of the company's investigational new drug application to begin Phase 1 clinical studies with its AM-831 product. AM-831 is an innovative small molecule for the treatment of schizophrenia. It was discovered by ACADIA and is being developed in collaboration with Meiji Seika Pharma Company Limited, a Japanese pharmaceutical company.…